Basic and clinical studies of faropenem in pediatric infection

Ryochi Fujii, Toshiaki Abe, Takeshi Tajima, Itaru Terashima, Hidenori Meguro, Hajime Sato, Kenji Niino, Hiroyuki Suzuki, Yoshikiyo Toyonaga, Hironori Nakamura, Keisuke Sunakawa, Takao Yokota, Hironobu Akita, Satoshi Iwata, Yoshitake Satoh, Tatsuo Kato, Naoichi Iwai, Haruhi Nakamura, Mitsunobu Miyazu, Keiko ItohKuniyoshi Kuno, Hitoshi Kamiya, Kenji Kitamura, Minoru Sakurai, Takashi Nakano, Haruki Mikawa, Masaru Kubota, Hidekazu Nakato, Setsuko Ito, Toru Momoi, Akira Yoshida, Tadafumi Nishimura, Kumiko Sugita, Shigeyuki Aoki, Michio Takagi, Yohnosuke Kobayashi, Minoru Kino, Hirohiko Higashino, Yutaka Kobayashi, Tsunekazu Haruta, Seikyo Furukawa, Takashige Okada, Takashi Okamoto, Takanori Sekiguchi, Yasuhiro Kuroda, Suguru Matsuoka, Takanobu Kurashige, Hiroshi Wakiguchi, Fumihiko Hamada, Taisuke Okada, Akihisa Nagao, Seiji Watanabe, Hiroshi Matsuda, Kaichi Kida, Masatoshi Hayashi, Takashi Motohiro, Shoichi Handa, Shuji Yamada, Shin Ichiro Oki, Yoichiro Yoshinaga, Keiko Oda, Yasutaka Sakata, Hirohisa Kato, Fumio Yamashita, Shoichi Imai, Hirokazu Sasaki, Jun Monta, Masafumi Aramaki, Yoshinori Matsuguma, Tomoshige Hirata, Nobuo Tanaka, Hisaaki Araki, Kiyotaka Nagayama, Masao Hayashi, Chikai Yasuoka, Eiichiro Ono, Ken Yuge, Nobuo Hashimoto, Keiko Sueyoshi, Kaoru Kubota, Akira Kawakami, Emi Higuchi, Toru Nishiyama, Kaoru Tominaga, Naoki Kuda, Tatsuhiko Koga, Tamotsu Fujimoto, Hiroshi Hayakawa, Toru Sugimura

Research output: Contribution to journalArticle

Abstract

Newly developed faropenem (FRPM) was evaluated clinically and pharmacokinetically in pediatrics as follows. 1. Efficacy The clinical efficacy was determined in 494 cases. The efficacy rate was 91.9% (271/295) in 295 patients from whom the above causal agents were isolated and 93.0% (185/199) in 199 patients without isolation of the agent. The bacteriological eradication rate was 82.5% (250/303 strains). The MICs of FRPM for penicillin resistant Streptococcus pneumoniae (PRSP) were ≤0.025 to 0.2 μg/ml. In all 10 cases, the clinical efficacy was more than good. The bacteriological eradication rate was 6 out of 8. The clinical efgcacy rate for cases which were non-responsive to previous chemotherapy was 89.3% (50/56). 2. Safety Side effects were observed in 6.6% (36/548) of the evaluated cases for safety. These were diarrhea, loose stool, gluteal candidiasis, urticaria and rash. There were abnormal laboratory findings in 37 cases including elevation of eosinophile, GPT, GOT, γ-GTP. None of the side effects or abnormal laboratory findings were serious. 3. Palatability of the drug The palatability of the drug was quite good. It was evaluated as more than moderate by 99.3% (555/559) of the patients. From the above results FRPM is considered to be quite useful in pediatric infections including PRSP infections.

Original languageEnglish
Pages (from-to)888-890
Number of pages3
JournalJapanese Journal of Chemotherapy
Volume45
Issue number10
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Basic and clinical studies of faropenem in pediatric infection'. Together they form a unique fingerprint.

Cite this